Pictet Asset Management
NTLA icon

Pictet Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Pictet Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$217K Buy
16,933
+5,429
+47% +$69.2K ﹤0.01% 1898
2025
Q4 		$103K Buy
+11,504
New +$158K ﹤0.01% 2018
2024
Q4 		– Sell
-1,394,911
Closed -$28.7M – 2073
2024
Q3 		$28.7M Buy
1,394,911
+650,879
+87% +$15M 0.03% 400
2024
Q2 		$16.7M Sell
744,032
-61,071
-8% -$1.45M 0.02% 518
2024
Q1 		$22.1M Sell
805,103
-78,367
-9% -$2.18M 0.02% 476
2023
Q4 		$26.9M Sell
883,470
-53,847
-6% -$1.55M 0.03% 408
2023
Q3 		$29.6M Buy
+937,317
New +$36.4M 0.04% 369

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Pictet Asset Management's NTLA Position: Q1 2026 in Review

Pictet Asset Management increased its Intellia Therapeutics (NTLA) stake by 47% in Q1 2026, buying an estimated $69.2K and bringing the position to 16,933 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #1898.

Pictet Asset Management first reported a position in NTLA in Q3 2023 and has held it in 7 quarters since. The position peaked at $29.6M in Q3 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Pictet Asset Management held 16,933 shares of Intellia Therapeutics worth $217K as of Q1 2026.
  • Pictet Asset Management bought 5,429 Intellia Therapeutics shares in Q1 2026, an estimated $69.2K.
  • Intellia Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #1898 holding.
  • Pictet Asset Management first reported a position in Intellia Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • Pictet Asset Management's Intellia Therapeutics position peaked at $29.6M in Q3 2023.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.